An insider from Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) increased its participation in the previous year

To look at Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) insider trading over the past year, we can see that insiders were net buyers. That is, there were more shares bought by insiders than shares sold.

While insider trading isn’t the most important thing when it comes to long-term investing, we think it makes perfect sense to keep tabs on what insiders are doing.

See our latest analysis for Shanghai Bio-heart Biological Technology

The past 12 months of insider trading in Shanghai Bio-heart Biological Technology

Over the past year, we can see that the largest insider buy was made by insider Ching Hung Chau for HK$395,000 worth of shares, at around HK$19.74 per share. While we like to see insider buying, we note that this big buy was significantly below the recent price of HK$68.95. Because the stock was purchased at a lower price, this particular purchase tells us little about what insiders think of the stock’s current price.

Ching Hung Chau has purchased 26,500 shares over the past 12 months at an average price of HK$20.78. The chart below shows insider trading (by companies and individuals) over the past year. If you want to know exactly who sold, how much and when, just click on the chart below!

SEHK:2185 Insider Trading Volume August 12, 2022

There are always plenty of stocks that insiders are buying. So if it suits your style you can check each stock one by one or you can take a look at this free list of companies. (Hint: insiders bought them).

Insider ownership

For an ordinary shareholder, it is worth checking how many shares are held by company insiders. High insider participation often makes company management more concerned with the interests of shareholders. From what we can see in our data, insiders only hold about HK$1.8 million worth of shares in Shanghai Bio-heart Biological Technology. We note, however, that insiders may have an indirect interest through a private company or other corporate structure. It’s always possible that we’re missing something, but based on our data, it appears that insider ownership is minimal.

So what does this data suggest about Shanghai bio-core biotech insiders?

The fact that there has been no insider trading from Shanghai Bio-heart Biological Technology recently certainly does not bother us. On a more positive note, last year’s transactions are encouraging. Although we are not worried about insider trading, we would be more comfortable if they held more shares of Shanghai Bio-heart Biological Technology. So these insider trades can help us build a thesis on the stock, but it’s also helpful to know the risks this company faces. Every business has risks, and we’ve spotted 1 warning sign for Shanghai Bio-heart Biological Technology you should know.

If you’d rather check out another company – one with potentially superior finances – then don’t miss this free list of attractive companies, which have a high return on equity and low debt.

For the purposes of this article, insiders are persons who report their transactions to the relevant regulatory body. We currently record open market transactions and private dispositions, but not derivative transactions.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

Comments are closed.